News
EPIX
6.32
-5.95%
-0.40
Weekly Report: what happened at EPIX last week (0408-0412)?
Weekly Report · 4d ago
Weekly Report: what happened at EPIX last week (0401-0405)?
Weekly Report · 04/08 11:02
Essa Pharma: Statement of changes in beneficial ownership of securities
Press release · 04/05 22:39
Weekly Report: what happened at EPIX last week (0325-0329)?
Weekly Report · 04/01 11:00
Essa Pharma: Statement of changes in beneficial ownership of securities
Press release · 03/28 20:15
Weekly Report: what happened at EPIX last week (0318-0322)?
Weekly Report · 03/25 11:02
Weekly Report: what happened at EPIX last week (0311-0315)?
Weekly Report · 03/18 11:01
Weekly Report: what happened at EPIX last week (0304-0308)?
Weekly Report · 03/11 10:58
ESSA Pharma Shareholders Show Strong Support
TipRanks · 03/08 01:37
EXCLUSIVE-Norway's wealth fund pushes for more women on emerging market company boards
Norway's $1.6 trillion sovereign wealth fund pushes for more women on emerging market company boards. The fund holds stakes in around 8,800 companies globally, owns 1.5% of all listed stocks. Since 2021, the fund has pushed companies to boost the number of women on their boards. It will call on emerging markets companies in which it invests to appoint more women to their boards for first time.
Reuters · 03/06 09:00
Weekly Report: what happened at EPIX last week (0226-0301)?
Weekly Report · 03/04 11:01
Weekly Report: what happened at EPIX last week (0219-0223)?
Weekly Report · 02/26 11:12
Weekly Report: what happened at EPIX last week (0212-0216)?
Weekly Report · 02/19 11:14
Analysts Offer Insights on Healthcare Companies: ESSA Pharma (EPIX) and Rocket Pharmaceuticals (RCKT)
TipRanks · 02/13 16:20
Analysts Are Bullish on Top Healthcare Stocks: Puma Biotechnology (PBYI), ESSA Pharma (EPIX)
TipRanks · 02/13 16:10
ESSA Pharma: Q1 Earnings Insights
ESSA Pharma reported its Q1 earnings of $-0.14 on February 13. The company beat estimates by 17.65%. The company's revenue was down $0 from the same period last year. Last quarter the company beat on EPS by $0.09 and the share price rose 0.36%.
Benzinga · 02/13 14:10
ESSA Pharma GAAP EPS of -$0.14
Seeking Alpha · 02/13 14:08
ESSA Pharma Inc reports results for the quarter ended in December - Earnings Summary
ESSA Pharma Inc reports results for the quarter ended in December. Reported revenue was zero; analysts expected zero. The company reported a quarterly loss of $5.96 million. Shares had risen by 46.5% this quarter. The average analyst rating on the shares is "buy"
Reuters · 02/13 13:46
*Essa Pharma 1Q Research and Development Expenditures $5.4M >EPIX
Dow Jones · 02/13 12:10
*Essa Pharma: Cash Runway Sufficient to Fund Ops Beyond 2025 >EPIX
Dow Jones · 02/13 12:08
More
Webull provides a variety of real-time EPIX stock news. You can receive the latest news about Essa Pharma through multiple platforms. This information may help you make smarter investment decisions.
About EPIX
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.